{
    "medicine_id": "e4bf298bb936ed0633b10eed44e93b61dd017d8a",
    "platform_id": "DB00874",
    "metadata": {
        "name": "7 Select Maximum Strength 0 67 g Syrup",
        "composition": "0 67 g Guaifenesin",
        "clinical_particulars": {
            "therapeutic_indications": "Guaifenesin is an expectorant that is indicated for providing temporary symptomatic relief from congested chests and coughs which may be due to a cold bronchitis and or other breathing illnesses FDA Label F4510 L6079",
            "contraindications": {
                "disease": "The most prevalent signs and symptoms associated with an overdose of guaifenesin have been nausea and vomiting L6100 Although adequate and well controlled studies in pregnant women have not been performed the Collaborative Perinatal Project monitored 197 mother child pairs exposed to guaifenesin during the first trimester L6100 An increased occurrence of inguinal hernias was found in the neonates L6100 However congenital defects were not strongly associated with guaifenesin use during pregnancy in 2 large groups of mother child pairs L6100 Moreover guaifenesin is excreted in breast milk in small quantities L6100 Subsequently caution should be exercised by balancing the potential benefit of treatment against any possible risks L6100 Additionally an LD sub 50 sub value of 1510 mg kg rat oral has been reported for guaifenesin MSDS",
                "pregnancy": "NA",
                "machine_ops": "NA",
                "pharmacodynamics": "Guaifenesin is categorized as an expectorant that acts by enhancing the output of phlegm sputum and bronchial secretions via decreasing the adhesiveness and surface tension of such material F4516 Furthermore guaifenesin elicits an increased flow of less viscous gastric secretions that subsequently promote ciliary action all actions that ultimately change dry unproductive coughing to coughs that are more productive and less frequent F4516 Essentially by decreasing the viscosity and adhesiveness of such secretions guaifenesin enhances the efficacy of mucociliary activity in removing accumulated secretions from the upper and lower airway F4516",
                "excipients": "NA",
                "incompatibilities": []
            }
        },
        "revision_date": "2023-05-14"
    }
}